IBDASE
Mucosal protease and their inhibitors in inflammatory bowel disease: From etiopathogenetic insight to innovative therapy
| Coordinatore | UNIVERSITAET BERN
Organization address
address: Hochschulstrasse 4 contact info |
| Nazionalità Coordinatore | Switzerland [CH] |
| Sito del progetto | http://www.ibdase.org/ |
| Totale costo | 4˙120˙034 € |
| EC contributo | 2˙973˙550 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-03-01 - 2011-05-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAET BERN
Organization address
address: Hochschulstrasse 4 contact info |
CH (BERN) | coordinator | 0.00 |
| 2 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 0.00 |
| 3 |
ISTITUTO EUROPEO DI ONCOLOGIA SRL
Organization address
address: Via Filodrammatici 10 contact info |
IT (MILANO) | participant | 0.00 |
| 4 |
JOHANNES GUTENBERG UNIVERSITAET MAINZ
Organization address
address: SAARSTRASSE 21 contact info |
DE (MAINZ) | participant | 0.00 |
| 5 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 0.00 |
| 6 |
PROGENIKA BIOPHARMA SA
Organization address
address: "Parque Tecnologico de Zamudio, Edificio 801 -A-, Planta 2" contact info |
ES (DERIO - VIZCAYA) | participant | 0.00 |
| 7 |
SCIPROM SARL
Organization address
address: RUE DU CENTRE 70 contact info |
CH (Saint-Sulpice) | participant | 0.00 |
| 8 |
UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Organization address
address: VIA ORAZIO RAIMONDO 18 contact info |
IT (ROMA) | participant | 0.00 |
| 9 |
UNIVERSITE D'AUVERGNE CLERMONT-FERRAND 1
Organization address
address: Boulevard Francois Mitterand 49 contact info |
FR (Clermont-Ferrand) | participant | 0.00 |
| 10 |
UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
UK (SOUTHAMPTON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'IBDase addresses the etiology and pathogenesis of inflammatory bowel disease (IBD) with a multidisciplinary plan for innovative diagnosis and therapy focused on mucosal proteases and their inhibitors (P/PIs). The incidence of IBD, a multifactorial disease influenced by environmental factors in a background of complex genetic susceptibility, is rising, particularly among European children. Current therapies lack efficacy and specificity. The gut microflora plays a crucial role in IBD but the cause for this is still poorly understood. Research implicating P/PIs in gut mucosal inflammation requires further mechanistic insight and the P/PIs relevant in human IBD need to be identified. To this end we will identify human mucosal P/PI polymorphisms affecting expression levels and/or activity of P/PIs and analyse their genotype/phenotype associations in IBD patient cohorts across Europe. IBD-associated P/PIs will be characterised by biochemical properties, expression in human clinical samples and manipulation of experimental models. Their interaction with microflora will be examined in animal models with controlled colonisation of the gut and in vitro co-culture models of intestinal mucosa and bacteria. In vivo studies will use targeted, well-established and new mouse models and evaluate zebrafish as an IBD model. Molecular mechanisms for involvement of IBD specific P/PI gene variants in the inflammatory response will be proposed. Therapeutics development will focus on specific inhibition or promotion of proteolysis in the intestinal mucosa, and select at least three validated P/PI of the intestinal mucosa for follow-up in clinical trials. Embracing the concept of tailoring treatment to individual patient characteristics to increase efficacy and reduce side-effects, IBDase strengthens international visibility of IBD related research, policies and industry and fosters IBD related research to the benefit of European society in both patient care and economic interest.'